Trial Search Results

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: Hypo-fractionated Radiotherapy

Phase:

Phase 2

Eligibility


Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial
PSA level <10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores
involved.

   - Patients who have had any form of prior curative treatment (surgery, radiotherapy,
   cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3
   months duration will be allowed.

   - Adult men will be considered.

   - No life expectancy restrictions will apply.

   - Performance Status will not be considered.

   - No requirements for organ or marrow function will be made

   - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:- No prior prostate treatment will be allowed.

   - The use of other concurrent Investigational Agents will not be allowed.

   - No exclusion requirements due to co-morbid disease or incurrent illness.

   - No requirements regarding history of allergic reactions.

   - Pregnancy or nursing patients is not applicable (ie. patients are male).

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Gillian McFarlane
6507212034
Not Recruiting